STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy.

doi:10.1080/1120009X.2023.2203610

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy.

Journal of chemotherapy (Florence, Italy) - 1 Feb 2024

Wang Yan, Qi Huijie, Wang Tianxiao, Zhang Wenxin, Shi Xiaojin, Zhan Qiong, Li Qunyi, Zhong Mingkang

Abstract excerpt

A total of 162 non-small cell lung cancer (NSCLC) patients were divided into discovery (N = 68) and validation (N = 94) groups. Nine Janus kinase/Signal transducer and activator of transcription (JAK/STAT) pathway-related single nucleotide polymorphisms were selected to explore the potential associations between genetic polymorphisms and adverse drug reactions (ADRs). The TT genotype of STAT6 rs324011 was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to China

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Protein Kinase Inhibitors

Share to STAT3 Transcription Factor

Share to STAT6 Transcription Factor

Source

Open in PubMed

Identifiers

PMID: 37151185
DOI: 10.1080/1120009X.2023.2203610

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy.PMID 37151185Read ↗

Association of JAK/STAT pathway gene polymorphisms with EGFR-TKIs adverse drug reactions in patients with advanced NSCLCSemantic proximity Read ↗

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.Semantic proximity Read ↗

Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.Semantic proximity Read ↗

Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.Semantic proximity Read ↗

A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity Read ↗

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Semantic proximity Read ↗

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.Semantic proximity Read ↗

Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.Semantic proximity Read ↗

Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

[Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)].Semantic proximity Read ↗

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.